Trial
NCT01725672
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
Phase ITERMINATEDREGULATORYConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Diabetes Mellitus, Type 2
Intervention
Metformin, 500 mg extended release tablet
Why stopped
Due to changes in EMA guidelines on modified release dosage forms (Feb 2013; EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-12